Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Pembrolizumab used as adjuvant therapy for NSCLC can cause central adrenal insufficiency, presenting with nonspecific fatigue, nausea, and hyponatremia. In a 67‑year‑old patient, a markedly low morning cortisol and suppressed ACTH confirmed the diagnosis within ten weeks of treatment. Prompt IV glucocorticoids, fluid resuscitation, and transition to physiologic hydrocortisone averted adrenal crisis, while persistent ACTH suppression indicated permanent deficiency. The case led to permanent discontinuation of pembrolizumab, highlighting risk‑benefit decisions in the adjuvant setting.
A recent JAMA Network Open case‑control study of 8,493 hospitalized adults shows that 2024‑2025 COVID‑19 vaccines provided moderate protection against the JN.1 lineage, with overall effectiveness of 40% against hospitalization and up to 52% after 90‑179 days. Updated Moderna and...
Vie Ventures has hired immunology veteran Jeff Bluestone to strengthen its autoimmune‑focused venture portfolio. Bluestone, founder of the Immune Tolerance Network and former CEO of the Parker Institute for Cancer Immunotherapy, previously co‑founded Sonoma Biotherapeutics and created Tzield teplizumab, the...
Researchers reported that the novel KRAS G12D inhibitor LPM-5140276 markedly improves antitumor activity when paired with the SHP2 inhibitor RMC-4550. The combination demonstrated synergistic tumor regression in preclinical models of pancreatic and colorectal cancers harboring KRAS G12D mutations. Data suggest enhanced pathway...
The FNIH Biomarkers Consortium unveiled a “clock model” that uses a single blood test to forecast Alzheimer’s disease symptom onset 3‑4 years before clinical presentation. The model aggregates plasma biomarkers into a temporal trajectory, and a new web‑based visualization tool...
ViiV Healthcare presented results from the Phase III LATITUDE trial evaluating Cabenuva, a long‑acting injectable of cabotegravir and rilpivirine, in 453 adults with adherence challenges. Among 306 virally suppressed participants, the quarterly injection reduced cumulative regimen failure to 22.8% versus...
The Government Accountability Office (GAO) reports that the Department of Health and Human Services (HHS) conducts risk assessments for gain‑of‑function research but does not consistently share those findings with the public. While the research has expanded understanding of pathogen transmission,...
Researchers at Yangzhou and Nanjing Universities have created an oral polysaccharide‑engineered nanozyme—fucoidan‑cerium nanocomplexes (FucCeNCs)—to treat colitis‑associated anxiety and depression. The nanocomplex combines cerium’s superoxide dismutase‑like activity with fucoidan’s prebiotic properties, enabling simultaneous reactive oxygen/nitrogen species scavenging and gut microbiota modulation....
CRISPR Therapeutics shares rose over 12% after reporting Q4 2025 earnings that showed a larger‑than‑expected loss and minimal recognized revenue. The company’s flagship therapy CASGEVY generated $54 million in sales, but under its revenue‑sharing deal with Vertex only $0.86 million was recorded. CRISPR...
Gossamer Bio is set to announce results from its Phase 3 trial in pulmonary arterial hypertension (PAH) before the end of February. The readout follows a Phase 2 study that delivered modest, sub‑par efficacy, which the company attributes to an...
Researchers applied cyclic OSK (Oct4‑Sox2‑Klf4) gene therapy to memory‑encoding neurons in aged mice, achieving partial cellular reprogramming without full pluripotency. The intervention reversed senescence‑related gene expression, restored youthful epigenetic patterns, and normalized synaptic plasticity in both hippocampal and prefrontal engrams....
The FDA has reversed its earlier refusal-to-file and will review Moderna’s seasonal mRNA influenza vaccine, with a decision slated for August 5, 2026. Moderna now seeks full approval for adults aged 50‑64 and accelerated approval for those 65 and older. Meanwhile, Eli Lilly...
A preclinical study published in Reproductive and Developmental Medicine found that combining melatonin with zinc oxide nanoparticles mitigates cyclophosphamide‑induced reproductive toxicity in male rats. The antioxidant duo restored testosterone and luteinizing hormone levels, lowered oxidative stress markers, and preserved spermatogenic...
Merck (MSD) and Mayo Clinic have launched a research partnership that blends Mayo's Platform architecture and multimodal clinical‑genomic data with MSD's virtual‑cell technologies. The collaboration gives MSD direct access to de‑identified imaging, lab, molecular and notes data to train and...
Merck & Co (MSD) and Mayo Clinic have launched a research partnership that leverages AI, advanced analytics, and multimodal clinical‑genomic data to accelerate drug discovery and precision medicine. The collaboration merges Mayo’s Platform architecture and de‑identified datasets—including imaging, labs, molecular...
Alphabet’s Verily has introduced a free, self‑serve Standard tier for its Pre precision‑health platform, allowing researchers to access the Exchange catalog and Workbench environment with just a Google account. The rollout adds three high‑impact datasets: a single‑cell AML cohort from...
Researchers at the Technical University of Munich have created a bio‑hybrid coating that visibly signals UV‑A exposure by turning from green to red. The sensor embeds dry Escherichia coli cells loaded with the photoconvertible protein mEosFP, which undergoes an irreversible...
Researchers have engineered Au@MnFe‑Prussian Blue Analog yolk‑shell nanoparticles that combine a hollow cavity with a functional shell for biomedical use. The synthesis creates a ~75 nm interior, achieving roughly 50% loading efficiency for the chemotherapeutic doxorubicin. Partial etching and redeposition of...
Researchers introduced a donor‑acceptor (D‑A) molecular design that couples a rigid coplanar backbone with flexible side chains, dramatically raising near‑infrared molar extinction and fluorescence brightness. The resulting phenothiazine‑based photosensitizer, EL‑TPO2F, also exhibits strong type‑I reactive oxygen species (ROS) production and...
Swedish startup CubaseBio has emerged from stealth after raising €5.9 million in blended financing – a €2 million European Innovation Council grant plus €3.9 million from Voima Ventures, Nordic Science Investments, Illumina Ventures and other life‑science investors. The capital will accelerate development of...
Pennsylvania’s Greater Philadelphia corridor remains a biotech hotbed, housing over 1,200 life‑science firms including AstraZeneca, GSK and Johnson & Johnson. Eli Lilly announced a new injectable weight‑loss manufacturing plant in the Lehigh Valley, projected to create roughly 850 jobs by 2031....
If you’re interested in organoid biology and/or 3D bioelectronics, then check out our paper published today in Nature Biomedical Engineering, titled ‘Shape-conformal porous frameworks for full coverage of neural organoids and high-resolution electrophysiology,’ at https://t.co/Y7MzvRQKTm. This work introduces a technology...
Researchers who launch biotech startups often abandon evidence‑based decision‑making once they enter the boardroom, falling prey to technology myopia, base‑rate neglect, and confirmation bias. Their lack of formal training in commercialization, financial modeling, and competitive analysis amplifies these pitfalls, leading...
Scientists at Cornell University have created a wireless brain implant so small it can sit on a grain of salt, yet still record and transmit neural activity. The device uses light‑based optics for power and data, eliminating bulky wires and...
Foresite Capital marked its 15th anniversary by projecting a resurgence in biopharma venture capital, anticipating a year‑over‑year rise in financings and IPOs starting in 2026. The firm highlighted a surge to $149 billion in biopharma VC dollars in 2025 and a...
Super proud of Dr. Kelly Rich, senior postdoc in our lab who's pioneering nerve cell epigenetic age reversal to treat diseases such as ALS and Alzheimer's 🪨⭐️ https://open.spotify.com/episode/7nWkEH5li36oW9monEIG8B
Why are there intronic reads in your bulk RNA-seq data? You're not alone—it's common, and the reasons are more layered than you think. Let’s break it down. 🧵 https://t.co/SNJnohqHUM
Researchers at the Princess Máxima Center have produced the first multimodal single‑cell atlas of healthy pediatric bone marrow, profiling nearly 91,000 cells from nine donors aged two to 32. The atlas reveals that children’s marrow differs markedly from adult marrow in...
"I took part in a 2012 psilocybin trial. What I’m seeing now horrifies me" https://t.co/T1BLv6n59X via @statnews
Predicting when symptoms of Alzheimer's disease will occur with elevated p-tau217 blood test and a person's age, even 20+ years in advance @NatureMedicine https://t.co/EYaGglBh1H
Researchers at NYU Langone Health identified the integrated stress response protein lipocalin 2 (LCN2) as a key mediator that lets lung and pancreatic tumors evade immune attack. In mouse models, antibodies that block LCN2 restored T‑cell infiltration, slowed tumor growth, and...
This week's Biotech Scorecard newsletter: -- What to expect from $GOSS Gossamer Bio’s late-stage lung disease study -- A better, safer Alzheimer’s treatment? ProMis $PMN takes its shot https://t.co/YaA8kvUR4Z
👍Profusa is my pick for 2026. Fascinating technology to measure real time tissue biochemistry. This is a fundamental shift from blood to tissue to shine a new light on cellular status and metabolism. https://t.co/gfduGvgJTX @ProfusaInc #medicine $PFSA #diabetes
Pulse Biosciences reported its first commercial revenue of $86,000 from limited market release of the nPulse platform and Vibrance disposables. The company completed over 200 procedures across pilot programs and advanced multiple clinical studies, including FDA IDE clearance for the...
$INSM guides to 2026 Brinsupri sales of "at least $1B" in line with consensus. https://t.co/o7JhPKU3m1
A multinational consortium investigated how host genetics influence persistent Epstein‑Barr virus (EBV) infection. Using large‑scale genome‑wide association studies across diverse cohorts, the team identified several host loci that modulate viral load and serostatus. Functional analyses linked these loci to immune...
Researchers have developed a blood test that quantifies an abnormal form of tau protein, acting as a molecular clock to predict not only the likelihood of Alzheimer’s disease but also the timing of symptom onset. The study, published in Nature...
Vertex Pharmaceuticals reported fourth‑quarter 2025 revenue of $3.2 billion, a 10% year‑over‑year increase, and full‑year revenue of $12 billion, up 9%. The company highlighted strong growth in its cystic fibrosis (CF) franchise, with 7% global expansion and double‑digit gains in the...
Isomorphic Labs unveiled IsoDDE, a proprietary AI engine touted as an “AlphaFold 4”‑level breakthrough in drug discovery. The 27‑page technical report claims the model outperforms AlphaFold 3, the open‑source Boltz‑2, and traditional physics‑based methods in predicting binding affinity and antibody‑protein interactions. Researchers...
The Mood Stabilizer Genomics (MoStGen) Consortium analyzed 917 bipolar disorder patients to identify genetic predictors of response to antiepileptic mood stabilizers (AMS). Genome‑wide association studies revealed a robust association between lamotrigine response and variants in ROBO2, and a gene‑level signal...
Researchers from the Living Brain Project combined prefrontal cortex biopsies from 130 neurosurgical patients with intracranial recordings of dopamine, serotonin, and other neurotransmitters. Differential‑expression analyses of single‑nucleus and bulk RNA‑seq data revealed reproducible gene‑expression signatures that correlate with fast‑scan cyclic...
The paper proposes exercise mimetics—pharmacological agents that imitate endurance training—as a novel class of antidepressants. While regular physical activity cuts depression risk by about 18 percent, adherence challenges limit its real‑world impact. Exercise mimetics activate muscle signaling pathways and alter the...
Ardelyx reported Q4 2025 revenue of $110.3 million, driven primarily by a 92% year‑over‑year surge in IBSRELA sales to $78.2 million. The company raised its full‑year IBSRELA revenue guidance to $270‑$275 million and posted a net loss of roughly $1 million, while cash balances...
Insmed reported a $144.6 million net revenue for Brinsupri’s first full U.S. quarter, surpassing internal launch benchmarks. Management set a minimum $1 billion Brinsupri revenue target for 2026 and projected total company revenue to more than double 2025 levels, driven by continued...
Gilead Sciences reported total product sales of $28.9 billion for 2025, a 1% increase that topped the high end of its guidance. The HIV franchise generated $20.8 billion, up 6% overall and 10% on an underlying basis after removing the Medicare Part D...
Genentech’s oral BTK inhibitor fenebrutinib met its primary endpoint in the Phase III FENtrepid trial for primary progressive multiple sclerosis, showing non‑inferiority to Ocrevus and a 12% risk reduction in confirmed disability progression. The drug also delivered a 26% lower risk...
![[Therapeutics] Adaptive Deep Brain Stimulation in Parkinson's Disease](/cdn-cgi/image/width=1200,quality=75,format=auto,fit=cover/https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/3742a25a994e69efcb711edfa308902b.webp)
Adaptive deep brain stimulation (aDBS) introduces real‑time modulation of stimulation amplitude by tracking subthalamic beta activity, shifting Parkinson's therapy from fixed to physiomarker‑guided. Clinical trials report superior motor improvement, reduced stimulation‑related side effects, and markedly lower energy consumption compared with...
Researchers at RCSI have created a 3‑D biomaterial implant that releases PTEN‑targeting siRNA to injured spinal cord neurons, reactivating growth pathways. The scaffold replicates spinal cord mechanical properties and delivers RNA particles directly to the lesion site, silencing the PTEN...
Macro: US vaccine-policy swing heightens regulatory risk; FDA will review Moderna’s flu shot. Key: public dispute, amended filing; decision by Aug 5. Risk: political oversight. Trade: Buy MRNA. — Viktor Kopylov, PhD, CFA More insights: t.me/si14Kopylov
FDA Commissioner Marty Makary warned that the United States is falling behind China in early‑stage drug development, citing slower Phase 1 trial volumes and cumbersome regulatory steps. He identified three primary bottlenecks—hospital contracting, ethical review processes, and the IND application workflow—that...
